Skip to Main Content

Multicenter, Open Label, Phase 3 Trial of ATA129 for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)

Conditions

Immune System | Infectious Diseases

Phase III

What is the purpose of this trial?

This is a multicenter, open-label, single-arm phase 3 trial to assess the efficacy and safety of ATA129 for the treatment of Epstein Barr Virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of solid organ transplant (SOT) after failure of rituximab or rituximab plus chemotherapy.

  • Trial with
    Atara Biotherapeutics
  • Start Date
    03/11/2018
  • End Date
    11/29/2020
Trial Image

For more information about this study, contact:

Ricarda Tomlin

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/24/2018
  • Study HIC
    #2000021894